HOOK [NASD]
HOOKIPA Pharma Inc.
Index- P/E- EPS (ttm)-2.24 Insider Own7.80% Shs Outstand38.60M Perf Week-10.98%
Market Cap89.10M Forward P/E- EPS next Y-1.39 Insider Trans-0.33% Shs Float- Perf Month-8.33%
Income-76.40M PEG- EPS next Q-0.41 Inst Own63.00% Short Float- Perf Quarter-32.46%
Sales14.60M P/S6.10 EPS this Y-36.10% Inst Trans85.19% Short Ratio6.11 Perf Half Y-37.40%
Book/sh3.83 P/B0.40 EPS next Y8.80% ROA-48.50% Target Price6.75 Perf Year-83.51%
Cash/sh2.43 P/C0.63 EPS next 5Y5.00% ROE-64.80% 52W Range1.25 - 9.45 Perf YTD-33.91%
Dividend- P/FCF- EPS past 5Y- ROI-86.30% 52W High-82.43% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low32.84% ATR0.14
Employees131 Current Ratio5.50 Sales Q/Q-73.60% Oper. Margin- RSI (14)50.44 Volatility7.39% 8.90%
OptionableYes Debt/Eq0.04 EPS Q/Q19.60% Profit Margin- Rel Volume0.35 Prev Close1.54
ShortableYes LT Debt/Eq0.01 EarningsMay 16 BMO Payout- Avg Volume650.79K Price1.66
Recom1.70 SMA20-1.92% SMA504.15% SMA200-38.85% Volume197,696 Change7.82%
Nov-12-21Downgrade Morgan Stanley Overweight → Equal-Weight $6
Apr-08-21Initiated Morgan Stanley Overweight $19
Nov-03-20Initiated Truist Buy $21
Oct-26-20Initiated JMP Securities Mkt Outperform $19
Oct-19-20Resumed H.C. Wainwright Buy $16
Sep-27-19Initiated H.C. Wainwright Buy $15
May-13-19Initiated RBC Capital Mkts Outperform $23
May-13-19Initiated BofA/Merrill Buy $17
Jun-21-22 09:00AM  
Jun-09-22 07:00AM  
Jun-05-22 09:00AM  
Jun-03-22 07:00AM  
May-26-22 05:15PM  
May-18-22 06:41AM  
May-16-22 08:15AM  
07:00AM  
May-12-22 05:25PM  
May-09-22 08:25AM  
07:00AM  
May-05-22 06:05PM  
May-03-22 07:00AM  
May-02-22 07:00AM  
Apr-28-22 09:15AM  
Apr-20-22 07:00AM  
Apr-13-22 11:40AM  
11:01AM  
07:00AM  
Mar-24-22 08:15AM  
07:00AM  
Mar-22-22 07:00AM  
Mar-17-22 07:00AM  
Mar-10-22 03:00PM  
Mar-08-22 04:51PM  
Mar-03-22 10:05AM  
Mar-02-22 07:00AM  
Mar-01-22 04:01PM  
Feb-16-22 08:17AM  
Feb-15-22 04:06PM  
Feb-09-22 07:00AM  
Jan-18-22 07:00AM  
Jan-04-22 07:00AM  
Dec-03-21 07:00AM  
Nov-12-21 07:00AM  
Nov-10-21 07:45AM  
06:30AM  
Nov-09-21 04:01PM  
Nov-04-21 03:01PM  
Nov-03-21 08:18AM  
Oct-26-21 09:33AM  
Oct-14-21 07:00AM  
Oct-07-21 04:05PM  
Sep-16-21 11:24AM  
Sep-15-21 08:43AM  
07:38AM  
07:00AM  
Sep-07-21 10:00AM  
Aug-27-21 09:00AM  
Aug-12-21 08:35AM  
07:00AM  
Aug-05-21 03:01PM  
05:30AM  
Aug-03-21 07:00AM  
Jul-26-21 11:01AM  
Jun-28-21 04:51AM  
Jun-10-21 07:30AM  
Jun-08-21 06:38AM  
Jun-07-21 06:00PM  
May-20-21 07:00AM  
May-19-21 08:36AM  
May-12-21 10:31AM  
07:00AM  
May-10-21 08:42AM  
May-05-21 03:00PM  
May-03-21 07:00AM  
Apr-29-21 07:00AM  
Apr-28-21 02:56AM  
Apr-14-21 08:00AM  
Apr-10-21 08:31AM  
Mar-18-21 08:25AM  
07:33AM  
07:00AM  
Mar-11-21 12:30PM  
Mar-09-21 07:00AM  
Mar-04-21 07:00AM  
Mar-03-21 07:00AM  
Feb-27-21 03:49AM  
Feb-16-21 07:00AM  
Jan-20-21 09:55AM  
Dec-11-20 04:20PM  
Dec-08-20 10:00PM  
04:01PM  
08:34AM  
Dec-07-20 11:33PM  
06:00AM  
Nov-30-20 06:00AM  
Nov-18-20 10:23AM  
Nov-15-20 08:26AM  
Nov-12-20 07:39AM  
07:15AM  
Nov-11-20 07:00AM  
Nov-03-20 07:00AM  
Oct-29-20 07:30AM  
Oct-26-20 10:08AM  
Oct-21-20 10:32AM  
Oct-19-20 08:00AM  
Sep-16-20 07:45AM  
07:00AM  
Sep-09-20 07:30AM  
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matushansky IgorChief Medical OfficerDec 21Option Exercise0.1022,8532,28591,544Jan 12 10:07 AM
Matushansky IgorChief Medical OfficerDec 21Sale2.4914,94937,22380,178Jan 12 10:07 AM